Dimitris Papamargaritis is Associate Professor and Honorary Consultant in Diabetes and Endocrinology at University of Leicester/ University Hospitals of Northamptonshire NHS Group (Kettering General Hospital) with special interest in obesity and type 2 diabetes.
His research interests include understanding the mechanisms that the novel obesity pharmacotherapies work and how to best combine lifestyle, pharmacological and surgical treatments for obesity and type 2 diabetes management. Currently he is the principal investigator for the OPAL trial, a platform trial investigating the impact of different lifestyle interventions and pharmacotherapies (and combination of them) on physical function. He has also completed a number of experimental trials investigating potential treatments for postprandial hypoglycaemia after bariatric surgery.
He is a National Clinical Fellow of the European Association for the Study of Obesity, a member of the clinical subcommittee of the Association for the Study of Obesity (lead for the Centres for Obesity Management) and a member of the academic committee of the Association of British Clinical Diabetologists. He has also co-founded the ABCD Diabetes Update course.
